Introduction from Lynne Berry CBE, Chair of HTA
Thank you for your interest in the role of Board Member of the Human Tissue Authority. These are important and demanding times for the health sector, for innovation in the life sciences and for issues about public trust and professional confidence. Consequently, our role as the regulator for the ethical use of human tissue has never been more vital.
We and the other regulators in the health system and the life sciences are increasingly collaborating to find ways of sharing data and our understanding of risk as well as developing shared services for support systems such as finance, IT and HR. We have co-located with many of the other regulators which is enabling us to build on the increased joint working we undertook during the pandemic. Together we are developing our ability to learn about new approaches to digitally enabled inspection and assurance as well as discussing wider developments in regulation and the life sciences and issues of joint concern about patient safety and public confidence.
Our new Board Members will have opportunities to be part of shaping the HTA’s future and its strategy. They will also have some challenges: grasping the potential for improvement as a result of greater collaboration; the potential of even greater risk-based regulation and data-driven intelligence; increasing the diversity of our workforce; support for the life sciences; maintaining trust and confidence in our work are just a few of these challenges. As a non-executive Board Member, you will also be able to encourage joint ways of developing the expertise and skills of our staff, inform our engagement with our varied stakeholders and reinforce our commitments to equality and inclusion.
If you have the skills and expertise to undertake the role of a Board Member and if you would enjoy the opportunity to contribute to our work at a very important time, I do hope you will consider applying for one of these important positions.
Lynne Berry CBE
Human Tissue Authority
As a Member of the Human Tissue Authority (HTA) you will:
- Support the Chair in setting the strategic direction of the HTA, encouraging and enabling the HTA to be a first-class regulator of human tissue;
- Support the Chair in developing the HTA in-line with the organisation’s strategic aims while maintaining a positive, constructive and appropriate relationship with its stakeholders to ensure confidence in the work of the HTA;
- Provide an independent view, a substantive contribution, and constructive challenge at Board meetings and sub committees;
- Monitor the performance of the HTA’s Executive, holding it to account for the delivery of the HTA’s business plan, HM Treasury and Department of Health and Social Care requirements;
- Undertake Living Organ Donation Panel work as required.
The HTA’s key priority is
to maintain public and professional confidence in the removal, storage and use
of human tissue by ensuring that these activities are undertaken safely and
ethically, and with proper consent.
The HTA was established
as an Executive Non-Departmental Public Body on 1 April 2005 under the Human
Tissue Act 2004. It also acts as a Competent Authority in relation to EU
legislation covering tissues and cells used in patient treatment, and organ
donation and transplantation.
The HTA licences
organisations that remove, store and use human tissue and organs for purposes
such as research, transplantation, post-mortem examination, anatomical
examination and public display, as set out in its governing legislation.
The HTA publishes Codes
of Practice and Standards relating to the conduct of activities within its
remit and superintends compliance with standards through a risk-based programme
of audit and inspection. It also plays a regulatory role in living organ
donation, ensuring that valid consent is given, and no coercion or reward takes
The HTA’s remit under the
Human Tissue Act extends to England, Wales, and Northern Ireland. It also
carries out some functions (in relation to EU legislation, regulating living
donation, and keeping of registers), on behalf of the Scottish Government.
Since December 2015, the Human Transplantation (Wales) Act 2013 has governed
consent for organ and tissue donation in Wales, for which the HTA has produced
a Code of Practice and oversees compliance.
In addition to its roles
in licensing, inspection, and approving living organ donations, the HTA has a
statutory duty to provide advice and guidance to the public, and professionals,
on activities within its remit. It also has a duty to monitor developments and
advise the Secretary of State, and counterparts in devolved administrations, on
As a regulator, the HTA
seeks to work with stakeholders to encourage improvement, remaining accessible
and responsive to a changing environment and the needs of the organisations it
regulates. It is regarded as being in a unique position to comment and offer
guidance on challenging issues which fall on the edge of its regulatory remit
The HTA works closely with
other regulators and industry to ensure that regulation supports innovation,
whilst protecting public confidence. In the context of Government focus on its
industrial strategy and the life sciences, HTA has identified various
opportunities for improving the current legislative framework. This will become
ever more necessary as the technology and science moves on and regulation will
need to remain apace.
The Authority’s Chair and
Members are appointed by the Secretary of State for Health and Social Care. The
Chair and half of the members are lay, with the remainder being professionals
drawn from some of the groups who are affected by the legislation.
Business Plan and
Guidance for the Public: https://www.hta.gov.uk/guidance-public
Board meetings are held either virtually or at 2 Redman Place, Stratford, London E20 1JQ.
21 September 2023 – virtual
7 December 2023 – London
7 March 2024
27 June 2024
19 September 2024
5 December 2024